BioMetas Named Title Sponsor for RESI Partnering Events in 2025 and 2026

FOR IMMEDIATE RELEASE

BioMetas Named Title Sponsor for RESI Partnering Events in 2025 and 2026
Boston, MA – March 17, 2025

By Dennis Ford, Founder and CEO of Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) is pleased to announce that BioMetas will serve as the “Title Sponsor” for all 2025 and 2026 Redefining Every-Stage Investments (RESI) partnering events. This strategic partnership highlights BioMetas’ dedication to advancing early-stage therapeutics by offering world-class preclinical discovery assay services specifically designed for emerging biotech companies focusing on Oncology and Immunology Therapeutic area.

BioMetas: Supporting the Next Generation of Therapeutic Startups
BioMetas is headquartered in Shanghai, China, with a Business Development presence in Cambridge, Massachusetts, U.S.A., allowing the company to serve biotech startups across global innovation hubs. BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research biological assay services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, DMPK, protein science, and immunology, BioMetas enables startups to progress their drug discovery programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas supports biotech companies de-risk their assets and position them for successful global partnering opportunities worldwide.

RESI Partnership: Expanding Global Opportunities for Startups
As Title Sponsor of all RESI 2025 and 2026 events, BioMetas will play a key role in fostering critical connections between early-stage biotech startups, global investors, and licensing partners. RESI, known for its highly curated networking opportunities, provides a unique platform where entrepreneurs can showcase their innovations, secure funding, and establish strategic partnerships.

Through this partnership, BioMetas will work closely with LSN to enhance the RESI experience for participating startups by providing tailored insights on preclinical discovery strategies, milestone planning, and investor readiness. Additionally, BioMetas will contribute to RESI programming, offering thought leadership on critical topics such as preclinical de-risking, translational science, and best practices for early-stage biotech fundraising.

Leadership Perspective
“We are excited to align BioMetas’ expertise in preclinical development with the RESI global partnering platform,” said Dennis Ford, Founder & CEO of Life Science Nation. “This sponsorship features BioMetas’ dedication to supporting the next wave of breakthrough therapeutics and accelerating their path to worldwide commercialization.”

“BioMetas is committed to providing best-in-class preclinical biological assays that empower biotech startups,” added Simon Hua, Chairman of BioMetas Group. “We’re keen to provide robust preclinical discovery solutions that advance biotech startups. Partnering with RESI, we’re bridging early-stage companies with the right investors to drive innovation.”

About Life Science Nation (LSN)
Life Science Nation accelerates the funding of early-stage life science companies by bridging entrepreneurs with global investors and strategic partners through its RESI partnering events and Global Partnering Campaigns.

About BioMetas
BioMetas is a leading worldwide provider of preclinical drug discovery services, offering comprehensive solutions that help biotech startups advance from concept to clinical readiness. Our Laboratories are based in Shanghai, China, with a Business Development office in the Hub of Cambridge, Massachusetts, U.S.A.. Through its expertise and commitment to high quality with fast data cycle-time, BioMetas enables life science innovators to develop transformative therapies efficiently and cost-effectively.

Learn more about BioMetas: https://biometasgroup.com/
For inquiries, contact Kelvin Lam (U.S.-based), Vice President, Head of Business Development at kelvin.lam@biometasgroup.com, or connect with him on LinkedIn.

For more information on RESI 2025 and 2026 events and strategic partnership opportunities, please contact: resi@lifesciencenation.com